Sanofi and Seoul National University Hospital Sign MOU for 'Future Clinical Innovation'

"More Precise and Effective Outcomes Expected When Innovative Technologies Are Integrated"

The Korean subsidiary of global healthcare company Sanofi signed a memorandum of understanding (MOU) with Seoul National University Hospital on June 2 for 'Innovation in the Future Clinical Trial Environment.'

Officials from global healthcare company Sanofi and Seoul National University Hospital are taking a commemorative photo after signing a memorandum of understanding (MOU) on the 2nd for 'Innovation in the Future Clinical Trial Environment.' Sanofi

According to Sanofi on June 4, this agreement is part of a strategic collaboration between the two organizations to jointly lead data-driven, patient-centered global clinical research. They plan to build a technology-based future clinical environment together and to develop collaborative models that can be applied in real-world settings.

This MOU aims to establish an integrated research model that goes beyond simply improving clinical trial efficiency, encompassing: enhancing participant-centered clinical experiences; strengthening data-driven decision-making systems; and connecting with global clinical research networks. To achieve these goals, the two organizations will create a data-centric clinical environment using digital technologies and will gradually identify demonstration projects that can be applied to clinical sites both in Korea and abroad.

Through this collaboration, Sanofi plans to help build a sustainable research ecosystem to achieve the ultimate goals of improving patients' quality of life and expanding access to treatment. The company also intends to focus on the practical development of clinical trials so that the clinical trial innovation model based on digital technologies can be realistically applied and established in Korea's medical field.

Bae Kyung-eun, Country Lead of Sanofi Korea, stated, "Clinical trials are not just research, but a crucial stage in healthcare that is directly linked to patients' lives. When innovative technologies such as digital solutions and artificial intelligence (AI) are integrated, patients can expect more precise and effective outcomes. This will serve as a pivotal turning point, enabling the entire clinical trial process to be designed with greater precision and flexibility. We anticipate that this will lead to meaningful changes that enhance both the convenience and trust of clinical trial participants."

Kim Yongjin, Director of the Biomedical Research Institute at Seoul National University Hospital, said, "The digital transformation of the clinical trial environment is an essential change for achieving patient-centered care and improving research efficiency. Together with Sanofi, we will prioritize patient-centered values and work to build a digital clinical trial model that enhances both participant experience and research quality."